2018 Partnerships & Pipeline

Each January, San Francisco buzzes all the more as a hub of life science collaboration. Partnerships are forged as thousands of innovators descend on the city for the J.P. Morgan Healthcare Conference – and we are certainly among them.

Lilly is in the early stages of a growth period catalyzed by recently launched products. Our pipeline’s potential remains strong, with new medicines in development to treat a range of diseases. Here are two things that we are talking about at JPM:

  1. Launching With Excellence

    • We have launched nine new medicines since 2014 for patients with unmet needs – and we expect to launch 11 more by 2023.
    • Lilly is focused on launch excellence so that physicians understand our new medicines and patients have access to them.
  2. Accelerating Innovation and Replenishing Our Pipeline
    • Lilly’s “Next Generation” initiatives in research and development have reduced the time to bring medicines to patients by two years, aiming to cut that even more.
    • We continue to evaluate external innovation opportunities – through acquisitions, alliances, licensing and our growing venture capital portfolio. We expect to source one-third of our pipeline by way of partnerships.

JPMHC18 V2 Lilly.com-940

This week in San Francisco holds much promise for partnerships, and thus the future of our pipeline. And this goal remains: getting high-quality medicines to patients as fast as we can.

Are you interested in collaborating with us? Discover more here. You can follow our #JPM18 coverage on Twitter at @LillyPad.

Collaborate With Us 

Tell us about your idea, technology or innovation and how we can work together to bring it to life.

Scientific Areas of Interest
Scientific Partnering
David A. Ricks Chairman and CEO, Lilly

"We’re trying to change the frontiers of what’s possible in medicine. Our vision is to change patients’ expectations – to provide a new sense of hope for people suffering from some of the world’s most debilitating diseases."